Drug Trial Radar · NCT03564964
Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Sep 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
No longer available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Suven Life Sciences LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2018
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 50 years, up to 85 years
Summary
As written by the sponsor on the registry.
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria. Subjects will not be evaluated for efficacy and safety during the expanded access.
Conditions
- Alzheimer Disease
- Dementia
- Cognition Disorders
Interventions
SUVN-502Drug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.